Phase I single-centre, placebo-controlled abuse liability trial of orally administered benzhydrocodone/paracetamol (KP 201), compared with hydrocodone/paracetamol.

Trial Profile

Phase I single-centre, placebo-controlled abuse liability trial of orally administered benzhydrocodone/paracetamol (KP 201), compared with hydrocodone/paracetamol.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Benzhydrocodone/paracetamol (Primary) ; Hydrocodone/paracetamol
  • Indications Pain
  • Focus Adverse reactions
  • Sponsors KemPharm
  • Most Recent Events

    • 12 Sep 2017 According to a company media release, KemPharm has responded to the Complete Response Letter (CRL) received on June 13, 2016 by submitting an amended New Drug Application (NDA) for Apadaz. The FDA has notified the Company with the determination that the NDA application for Apadaz is complete and has assigned February 23, 2018 as the expected date by which an approval decision will be determined.
    • 05 May 2016 According to a KemPharm media release, the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the US FDA voted in favor of approval for benzhydrocodone/paracetamol hydrochloride combination (Apadaz) for the management of acute pain that requires opioid and voted against inclusion of abuse deterrent labeling for the product.
    • 19 Feb 2016 According to a KemPharm Inc. media release, the U.S. FDA accepted New Drug Application for KP201/APAP and granted priority review. Under the the Prescription Drug User Fee Act the U.S. FDA has set a target action date of 9-June-2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top